Literature DB >> 19506019

Hereditary inclusion body myopathy-linked p97/VCP mutations in the NH2 domain and the D1 ring modulate p97/VCP ATPase activity and D2 ring conformation.

Dalia Halawani1, Andréa C LeBlanc, Isabelle Rouiller, Stephen W Michnick, Marc J Servant, Martin Latterich.   

Abstract

Hereditary inclusion body myopathy associated with early-onset Paget disease of bone and frontotemporal dementia (hIBMPFTD) is a degenerative disorder caused by single substitutions in highly conserved residues of p97/VCP. All mutations identified thus far cluster within the NH(2) domain or the D1 ring, which are both required for communicating conformational changes to adaptor protein complexes. In this study, biochemical approaches were used to identify the consequences of the mutations R155P and A232E on p97/VCP structure. Assessment of p97/VCP oligomerization revealed that p97(R155P) and p97(A232E) formed hexameric ring-shaped structures of approximately 600 kDa. p97(R155P) and p97(A232E) exhibited an approximately 3-fold increase in ATPase activity compared to wild-type p97 (p97(WT)) and displayed increased sensitivity to heat-induced upregulation of ATPase activity. Protein fluorescence analysis provided evidence for conformational differences in the D2 rings of both hIBMPFTD mutants. Furthermore, both mutations increased the proteolytic susceptibility of the D2 ring. The solution structures of all p97/VCP proteins revealed a didispersed distribution of a predominant hexameric population and a minor population of large-diameter complexes. ATP binding significantly increased the abundance of large-diameter complexes for p97(R155P) and p97(A232E), but not p97(WT) or the ATP-binding mutant p97(K524A). Therefore, we propose that hIBMPFTD p97/VCP mutants p97(R155P) and p97(A232E) possess structural defects that may compromise the mechanism of p97/VCP activity within large multiprotein complexes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19506019      PMCID: PMC2725746          DOI: 10.1128/MCB.00252-09

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  33 in total

1.  Mobilization of processed, membrane-tethered SPT23 transcription factor by CDC48(UFD1/NPL4), a ubiquitin-selective chaperone.

Authors:  M Rape; T Hoppe; I Gorr; M Kalocay; H Richly; S Jentsch
Journal:  Cell       Date:  2001-11-30       Impact factor: 41.582

2.  A major conformational change in p97 AAA ATPase upon ATP binding.

Authors:  I Rouiller; V M Butel; M Latterich; R A Milligan; E M Wilson-Kubalek
Journal:  Mol Cell       Date:  2000-12       Impact factor: 17.970

3.  Cdc48 (p97): a "molecular gearbox" in the ubiquitin pathway?

Authors:  Stefan Jentsch; Sebastian Rumpf
Journal:  Trends Biochem Sci       Date:  2006-12-04       Impact factor: 13.807

4.  TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations.

Authors:  Manuela Neumann; Ian R Mackenzie; Nigel J Cairns; Philip J Boyer; William R Markesbery; Charles D Smith; J Paul Taylor; Hans A Kretzschmar; Virginia E Kimonis; Mark S Forman
Journal:  J Neuropathol Exp Neurol       Date:  2007-02       Impact factor: 3.685

5.  Pathological consequences of VCP mutations on human striated muscle.

Authors:  Christian U Hübbers; Christoph S Clemen; Kristina Kesper; Annett Böddrich; Andreas Hofmann; Outi Kämäräinen; Karen Tolksdorf; Maria Stumpf; Julia Reichelt; Udo Roth; Sabine Krause; Giles Watts; Virginia Kimonis; Mike P Wattjes; Jens Reimann; Dietmar R Thal; Katharina Biermann; Bernd O Evert; Hanns Lochmüller; Erich E Wanker; Benedikt G H Schoser; Angelika A Noegel; Rolf Schröder
Journal:  Brain       Date:  2006-09-19       Impact factor: 13.501

6.  Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice.

Authors:  Conrad C Weihl; Sara E Miller; Phyllis I Hanson; Alan Pestronk
Journal:  Hum Mol Genet       Date:  2007-02-28       Impact factor: 6.150

7.  TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia.

Authors:  C C Weihl; P Temiz; S E Miller; G Watts; C Smith; M Forman; P I Hanson; V Kimonis; A Pestronk
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-10       Impact factor: 10.154

Review 8.  VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder.

Authors:  Virginia E Kimonis; Erin Fulchiero; Jouni Vesa; Giles Watts
Journal:  Biochim Biophys Acta       Date:  2008-09-18

9.  Impaired protein aggregate handling and clearance underlie the pathogenesis of p97/VCP-associated disease.

Authors:  Jeong-Sun Ju; Sara E Miller; Phyllis I Hanson; Conrad C Weihl
Journal:  J Biol Chem       Date:  2008-08-20       Impact factor: 5.157

10.  Mutations in p97/VCP induce unfolding activity.

Authors:  Andrea Rothballer; Nikolay Tzvetkov; Peter Zwickl
Journal:  FEBS Lett       Date:  2007-02-28       Impact factor: 4.124

View more
  62 in total

1.  Identification of Caspase-6-mediated processing of the valosin containing protein (p97) in Alzheimer's disease: a novel link to dysfunction in ubiquitin proteasome system-mediated protein degradation.

Authors:  Dalia Halawani; Sylvain Tessier; Dominique Anzellotti; David A Bennett; Martin Latterich; Andréa C LeBlanc
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

2.  A novel ATP-dependent conformation in p97 N-D1 fragment revealed by crystal structures of disease-related mutants.

Authors:  Wai Kwan Tang; Dongyang Li; Chou-chi Li; Lothar Esser; Renming Dai; Liang Guo; Di Xia
Journal:  EMBO J       Date:  2010-05-28       Impact factor: 11.598

3.  The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteins.

Authors:  Rosanna Piccirillo; Alfred L Goldberg
Journal:  EMBO J       Date:  2012-07-06       Impact factor: 11.598

4.  Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death.

Authors:  Paola Magnaghi; Roberto D'Alessio; Barbara Valsasina; Nilla Avanzi; Simona Rizzi; Daniela Asa; Fabio Gasparri; Liviana Cozzi; Ulisse Cucchi; Christian Orrenius; Paolo Polucci; Dario Ballinari; Claudia Perrera; Antonella Leone; Giovanni Cervi; Elena Casale; Yang Xiao; Chihunt Wong; Daniel J Anderson; Arturo Galvani; Daniele Donati; Tom O'Brien; Peter K Jackson; Antonella Isacchi
Journal:  Nat Chem Biol       Date:  2013-07-28       Impact factor: 15.040

5.  Altered intersubunit communication is the molecular basis for functional defects of pathogenic p97 mutants.

Authors:  Wai Kwan Tang; Di Xia
Journal:  J Biol Chem       Date:  2013-11-06       Impact factor: 5.157

Review 6.  Valosin containing protein associated fronto-temporal lobar degeneration: clinical presentation, pathologic features and pathogenesis.

Authors:  C C Weihl
Journal:  Curr Alzheimer Res       Date:  2011-05       Impact factor: 3.498

Review 7.  Regulation of molecular chaperones through post-translational modifications: decrypting the chaperone code.

Authors:  Philippe Cloutier; Benoit Coulombe
Journal:  Biochim Biophys Acta       Date:  2013-02-28

8.  Ubiquitin- and ATP-dependent unfoldase activity of P97/VCP•NPLOC4•UFD1L is enhanced by a mutation that causes multisystem proteinopathy.

Authors:  Emily E Blythe; Kristine C Olson; Vincent Chau; Raymond J Deshaies
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-16       Impact factor: 11.205

9.  The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group.

Authors:  Qiuyan Wang; Bidhan A Shinkre; Jin-gu Lee; Marc A Weniger; Yanfen Liu; Weiping Chen; Adrian Wiestner; William C Trenkle; Yihong Ye
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

10.  Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease.

Authors:  Jeong-Sun Ju; Rodrigo A Fuentealba; Sara E Miller; Erin Jackson; David Piwnica-Worms; Robert H Baloh; Conrad C Weihl
Journal:  J Cell Biol       Date:  2009-12-14       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.